BioNxt Solutions Inc. (FRA:BXT)
0.4470
+0.0220 (5.18%)
Last updated: Aug 1, 2025
Marathon Oil Revenue
BioNxt Solutions had revenue of 22.85K CAD in the twelve months ending March 31, 2025, down -88.95% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
22.85K CAD
Revenue Growth
-88.95%
P/S Ratio
3,506.37
Revenue / Employee
n/a
Employees
n/a
Market Cap
51.57M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
Dec 31, 2020 | 345.65K | 137.54K | 66.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 109.03B |
Siemens Energy AG | 37.44B |
Rheinmetall AG | 10.48B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Deutsche Bank Aktiengesellschaft | 30.07B |
BioNxt Solutions News
- 21 days ago - BioNxt Solutions Announces Convertible Debenture Unit Private Placement - Wallstreet:Online
- 24 days ago - BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology - Wallstreet:Online
- 25 days ago - BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase - Wallstreet:Online
- 5 weeks ago - BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets - Wallstreet:Online
- 2 months ago - BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent - Wallstreet:Online
- 2 months ago - Bionxt Solutions Provides Bi-Weekly MCTO Status Report - Wallstreet:Online
- 2 months ago - BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory - Wallstreet:Online
- 3 months ago - BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization - Wallstreet:Online